Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target boosted by JPMorgan Chase & Co. from $33.00 to $38.00 in a research note released on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other analysts have also recently weighed in on SNDX. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Stifel Nicolaus raised their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Citigroup upped their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright raised their price objective on shares of Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a report on Monday. Finally, Barclays boosted their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.64.

Syndax Pharmaceuticals Stock Performance

SNDX stock opened at $15.60 on Thursday. The company’s 50 day moving average price is $18.66 and its 200 day moving average price is $20.05. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -4.30 and a beta of 0.92. Syndax Pharmaceuticals has a fifty-two week low of $15.00 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same period in the prior year, the company posted ($0.73) earnings per share. Equities analysts forecast that Syndax Pharmaceuticals will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Syndax Pharmaceuticals in the 2nd quarter valued at approximately $27,000. Values First Advisors Inc. purchased a new stake in Syndax Pharmaceuticals during the third quarter worth $30,000. nVerses Capital LLC acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at $33,000. Quantbot Technologies LP purchased a new position in shares of Syndax Pharmaceuticals in the third quarter valued at $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).